Group 1: Online Marketing and Revenue - In 2023, online revenue reached 1.827 billion CNY, accounting for 67.5% of the main business income [1] - The online expense ratio increased due to the need for higher investment in traditional platforms and the early-stage inefficiencies of the interest e-commerce team [2] - The company aims to improve the conversion efficiency of interest e-commerce while reducing the online expense ratio [2] Group 2: Respiratory Product Sales and Future Growth - In Q1 2024, revenue from the respiratory support segment slightly decreased, primarily due to reduced demand for oxygen machines, while sales of ventilators and nebulizers increased [2] - The company plans to upgrade 3L and 5L oxygen machines and launch new products, including portable sleep ventilators and second-generation sleep machines [2] Group 3: Production Capacity and Self-manufactured Products - In 2023, the company achieved self-manufactured product revenue of 1.533 billion CNY, representing 56.66% of main business income [2] - The self-manufactured product ratio increased from 26% in 2019 to 56% in 2023, with a corresponding improvement in gross margin [2] Group 4: New Product Launches in 2024 - The company plans to launch several new products in 2024, including a 4G transmission blood pressure monitor and a blood glucose and uric acid monitoring system [3] - The rehabilitation aids segment will introduce new electric wheelchairs and nursing beds, while the respiratory support segment will focus on innovative products like direct current nebulizers [3] Group 5: Expansion in Hearing Aid Business - In 2023, the hearing aid segment generated revenue of 198 million CNY, a year-on-year increase of 64%, despite a net loss of 25.07 million CNY [4] - The company plans to accelerate the expansion of hearing aid centers through new openings and acquisitions in 2024 [4] Group 6: Dividend Policy - The company maintains a long-term, stable shareholder return mechanism, proposing a cash dividend of 12 CNY per 10 shares for the 2023 fiscal year [4] - In 2024, the company aims to increase the frequency of cash dividends based on operational performance and financial conditions [4]
可孚医疗(301087) - 2024年4月28日投资者关系活动记录表